A detailed history of Pensionmark Financial Group, LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Pensionmark Financial Group, LLC holds 7,752 shares of ARWR stock, worth $194,342. This represents 0.04% of its overall portfolio holdings.

Number of Shares
7,752
Previous 16,707 53.6%
Holding current value
$194,342
Previous $511,000 56.75%
% of portfolio
0.04%
Previous 0.07%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$27.21 - $39.48 $243,665 - $353,543
-8,955 Reduced 53.6%
7,752 $221,000
Q4 2023

Feb 14, 2024

BUY
$21.2 - $31.03 $41,340 - $60,508
1,950 Added 13.21%
16,707 $511,000
Q3 2023

Nov 14, 2023

SELL
$26.2 - $36.08 $5,633 - $7,757
-215 Reduced 1.44%
14,757 $396,000
Q2 2023

Aug 14, 2023

SELL
$25.16 - $41.38 $128,039 - $210,582
-5,089 Reduced 25.37%
14,972 $533,000
Q1 2023

May 15, 2023

SELL
$23.68 - $38.51 $13,379 - $21,758
-565 Reduced 2.74%
20,061 $509,000
Q4 2022

Feb 14, 2023

SELL
$28.0 - $40.56 $196,000 - $283,920
-7,000 Reduced 25.34%
20,626 $836,000
Q3 2022

Nov 14, 2022

SELL
$29.63 - $48.31 $59,852 - $97,586
-2,020 Reduced 6.81%
27,626 $913,000
Q2 2022

Aug 09, 2022

SELL
$27.79 - $50.61 $11,254 - $20,497
-405 Reduced 1.35%
29,646 $1.32 Million
Q1 2022

May 12, 2022

BUY
$39.62 - $69.97 $14,183 - $25,049
358 Added 1.21%
30,051 $1.38 Million
Q4 2021

Feb 11, 2022

BUY
$58.09 - $82.51 $237,123 - $336,805
4,082 Added 15.94%
29,693 $1.58 Million
Q3 2021

Nov 12, 2021

BUY
$58.38 - $84.96 $914,581 - $1.33 Million
15,666 Added 157.53%
25,611 $1.6 Million
Q2 2021

Aug 12, 2021

BUY
$62.15 - $90.32 $82,970 - $120,577
1,335 Added 15.51%
9,945 $824,000
Q1 2021

May 17, 2021

BUY
$61.35 - $90.47 $528,223 - $778,946
8,610 New
8,610 $584,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.65B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Pensionmark Financial Group, LLC Portfolio

Follow Pensionmark Financial Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pensionmark Financial Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pensionmark Financial Group, LLC with notifications on news.